君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01877 君实生物

已收盘 04-19 16:08:35

9.240

-0.410

-4.25%

最高9.600	最低9.240	成交量72.42万
今开9.600	昨收9.650	日振幅3.73%
总市值91.08亿	流通市值20.26亿	总股本9.86亿
成交额681.18万	换手率0.33%	流通股本2.19亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01877","market":"HK","secType":"STK","nameCN":"君实生物","latestPrice":9.24,"timestamp":1713514115029,"preClose":9.65,"halted":0,"volume":724200,"delay":0,"floatShares":219295700,"shares":985689871,"eps":-2.506814,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.41,"latestTime":"04-19 16:08:35","open":9.6,"high":9.6,"low":9.24,"amount":6811802,"amplitude":0.037306,"askPrice":9.33,"askSize":2000,"bidPrice":9.24,"bidSize":10800,"shortable":3,"etf":0,"ttmEps":-2.506813927074766,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1713749400000},"adr":0,"listingDate":1545580800000,"adjPreClose":9.65,"openAndCloseTimeList":[[1713490200000,1713499200000],[1713502800000,1713513600000]],"volumeRatio":0.991425,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688180","market":"SH","secType":"STK","nameCN":"君实生物","latestPrice":24.62,"timestamp":1713510000000,"preClose":24.94,"halted":0,"volume":4778277,"delay":0,"premium":"-65.27"}},"requestUrl":"/m/hq/s/01877","defaultTab":"news","newsList":[{"id":"2428395929","title":"君实生物(01877.HK)拟4月29日举行董事会会议批准一季度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2428395929","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2428395929?lang=zh_cn&edition=full","pubTime":"2024-04-17 16:32","pubTimestamp":1713342733,"startTime":"0","endTime":"0","summary":"格隆汇4月17日丨君实生物(01877.HK)发布公告，董事会兹通告谨定于2024年4月29日（星期一）举行董事会会议，以考虑及通过集团截至2024年3月31日止三个月未经审核的财务业绩。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041716322087880b8a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041716322087880b8a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427890287","title":"君实生物盘中异动 下午盘快速下挫5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427890287","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427890287?lang=zh_cn&edition=full","pubTime":"2024-04-16 14:19","pubTimestamp":1713248398,"startTime":"0","endTime":"0","summary":"2024年04月16日下午盘14时19分，君实生物股票出现异动，股价大幅跳水5.06%。截至发稿，该股报9.780港元/股，成交量79.2588万股，换手率0.36%，振幅7.57%。君实生物股票所在的生物技术行业中，整体跌幅为1.21%。其相关个股中，创胜集团-B、百奥赛图-B、和誉-B涨幅较大，振幅较大的相关个股有来凯医药-B、圣诺医药-B、乐普生物-B，振幅分别为24.28%、15.99%、13.41%。药品批发,药品委托生产。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161419597a530f45&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404161419597a530f45&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427802372","title":"智通AH统计|4月15日","url":"https://stock-news.laohu8.com/highlight/detail?id=2427802372","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2427802372?lang=zh_cn&edition=full","pubTime":"2024-04-15 16:15","pubTimestamp":1713168905,"startTime":"0","endTime":"0","summary":"智通财经APP数据显示，截止4月15日收盘，东北电气、弘业期货、浙江世宝分列AH溢价率前三位，溢价率分别为1155.81%、750.00%、640.00%；比亚迪股份、招商银行、紫金矿业分列AH溢价率末三位，溢价率分别为22.90%、23.84%、24.63%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1102475.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426772762","title":"智通AH统计|4月12日","url":"https://stock-news.laohu8.com/highlight/detail?id=2426772762","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426772762?lang=zh_cn&edition=full","pubTime":"2024-04-12 16:15","pubTimestamp":1712909705,"startTime":"0","endTime":"0","summary":"智通财经APP数据显示，截止4月12日收盘，东北电气、弘业期货、浙江世宝分列AH溢价率前三位，溢价率分别为1210.68%、734.11%、661.17%；比亚迪股份、招商银行、紫金矿业分列AH溢价率末三位，溢价率分别为20.01%、21.74%、23.49%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1101652.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426446202","title":"君实生物：截至目前公司没有口服降压药研发项目，","url":"https://stock-news.laohu8.com/highlight/detail?id=2426446202","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2426446202?lang=zh_cn&edition=full","pubTime":"2024-04-10 19:48","pubTimestamp":1712749712,"startTime":"0","endTime":"0","summary":"公司药品近年持续获得上市许可，好消息持续。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404101949388b09f324&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404101949388b09f324&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426171354","title":"君实生物获北向资金买入1284.68万元，累计持股1704.16万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426171354","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2426171354?lang=zh_cn&edition=full","pubTime":"2024-04-10 08:01","pubTimestamp":1712707309,"startTime":"0","endTime":"0","summary":"4月10日，巨灵财经数据显示，北向资金9日增持君实生物预估1284.68万元，累计持股1704.16万股，总计持有市值4.7亿元，占流通股比例2.23%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240410080153875c96d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240410080153875c96d4&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426159865","title":"君实生物04月09日获主力加仓315万元 环比增加400.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426159865","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426159865?lang=zh_cn&edition=full","pubTime":"2024-04-09 16:15","pubTimestamp":1712650559,"startTime":"0","endTime":"0","summary":"04月09日, 君实生物股价涨13.31%，报收11.24元，成交金额4082万元，换手率1.71%，振幅14.92%，量比3.73。君实生物今日主力资金净流入315万元，上一交易日主力净流入63万元，今日环比增加400.00%。该股近5个交易日上涨13.48%，主力资金累计净流入506万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入544万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404091616258b027587&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404091616258b027587&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426313980","title":"港股异动 | 生物医药股多数走高 康希诺生物(06185)涨超15% 多地出台创新药支持文件","url":"https://stock-news.laohu8.com/highlight/detail?id=2426313980","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426313980?lang=zh_cn&edition=full","pubTime":"2024-04-09 14:10","pubTimestamp":1712643009,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，生物医药股多数走高，CRO板块领涨，截至发稿，康希诺生物涨15.49%，报18.94港元；君实生物涨12.5%，报11.26港元；昭衍新药涨9.58%，报9.72港元；泰格医药涨6.6%，报34.1港元；药明合联涨6.3%，报19.92港元。其中，中国CRO市场增速高于全球，而临床CRO市场扩容明显。该行指出，中国制药行业逐步由生产销售仿制药向创新药转型，研发难度加大，扩大CRO需求。药政部门对创新药发展提出更高要求，更高研发风险下临床CRO作用将日益凸显。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1099871.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426185517","title":"港股异动 | 君实生物(01877)涨超6% 特瑞普利肾癌适应症获批 有望助推销售额提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2426185517","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426185517?lang=zh_cn&edition=full","pubTime":"2024-04-09 11:13","pubTimestamp":1712632383,"startTime":"0","endTime":"0","summary":"方正证券指出，特瑞普利肾癌独家适应症上市，有望推动销售额进一步增长。2023年，特瑞普利单抗销售收入约9亿元，同比增长约25%。此次肾癌独家适应症的获批，将有助于其销售额进一步提升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1099817.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426839421","title":"君实生物(01877)上涨5.44%，报10.46元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426839421","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2426839421?lang=zh_cn&edition=full","pubTime":"2024-04-09 11:03","pubTimestamp":1712631803,"startTime":"0","endTime":"0","summary":"4月9日，君实生物(01877)盘中上涨5.44%，截至11:03，报10.46元/股，成交689.35万元。上海君实生物医药科技股份有限公司主要业务是发现、开发和商业化创新疗法，特别是在肿瘤免疫疗法、自身免疫系统疾病、慢性代谢类疾病、神经系统疾病、感染类疾病等治疗方面。公司拥有卓越的创新药物发现能力、先进的生物技术研发、全产业链大规模生产技术和极具市场潜力的在研药品组合。截至2023年年报，君实生物营业总收入15.03亿元、净利润-22.82亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/09110340160993.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2426183827","title":"君实生物盘中异动 早盘快速拉升5.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426183827","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426183827?lang=zh_cn&edition=full","pubTime":"2024-04-09 11:03","pubTimestamp":1712631799,"startTime":"0","endTime":"0","summary":"2024年04月09日早盘11时03分，君实生物股票出现波动，股价快速上涨5.24%。截至发稿，该股报10.441港元/股，成交量67.2万股，换手率0.31%，振幅4.84%。君实生物股票所在的生物技术行业中，整体涨幅为0.05%。其相关个股中，康希诺生物、宜明昂科-B、来凯医药-B涨幅较大，振幅较大的相关个股有宜明昂科-B、康希诺生物、百奥赛图-B，振幅分别为13.35%、12.93%、12.90%。药品批发,药品委托生产。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240409110319861e41c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240409110319861e41c5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425966277","title":"太平洋给予君实生物买入评级 公司运营效率稳步提升，拓益海外商业化顺利推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2425966277","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2425966277?lang=zh_cn&edition=full","pubTime":"2024-04-08 17:49","pubTimestamp":1712569770,"startTime":"0","endTime":"0","summary":"太平洋04月08日发布研报称，给予君实生物（688180.SH，最新价：26.2元）买入评级。评级理由主要包括：1）2023年公司产品销售收入大幅增长，整体运营效率提升，亏损逐；2）2024年特瑞普利单抗国内医保适应症预计扩至10项，海外商业；3）2024年公司核心管线催化剂丰富。风险提示：研发或销售不及预期风险，行业政策风险。文章来源：每日经济新闻原标题：太平洋给予君实生物买入评级，公司运营效率稳步提升，拓益海外商业化顺利推进","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404081759328753f261&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404081759328753f261&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425026985","title":"君实生物PD-1获批肾癌一线治疗 未来或拓至大适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2425026985","media":"证券日报","top":-1,"share":"https://www.laohu8.com/m/news/2425026985?lang=zh_cn&edition=full","pubTime":"2024-04-08 11:03","pubTimestamp":1712545438,"startTime":"0","endTime":"0","summary":"本报记者徐一鸣见习记者金婉霞4月7日晚间，君实生物公告称，公司收到了国家药品监督管理局（NMPA）核准签发的《药品注册证书》，其特瑞普利单抗（商品名：拓益）联合阿昔替尼用于中高危的不可切除或转移性肾细胞癌患者的一线治疗的新适应症上市申请获得批准，这是我国首个获批的肾癌免疫疗法。新适应症的获批也意味着拓益的销售市场有望进一步拓宽。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404083035942363.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2425601620","title":"港股异动 | 君实生物(01877)涨近5% 特瑞普利单抗联合疗法获批一线治疗肾癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2425601620","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2425601620?lang=zh_cn&edition=full","pubTime":"2024-04-08 09:44","pubTimestamp":1712540645,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，君实生物(01877)涨近5%，截至发稿，涨4.73%，报10.18港元，成交额337.64万港元。消息面上，君实生物日前发布公告称，由公司自主研发的特瑞普利单抗联合阿昔替尼一线治疗中高危不可切除或转移性肾细胞癌患者的新适应症上市申请于近日获得国家药品监督管理局（NMPA）批准。这是特瑞普利单抗在中国获批的第八项适应症，也是我国首个获批的肾癌免疫疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1099137.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2425604551","title":"北向资金4月3日净买入君实生物-U22.01万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2425604551","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2425604551?lang=zh_cn&edition=full","pubTime":"2024-04-08 09:30","pubTimestamp":1712539836,"startTime":"0","endTime":"0","summary":"4月3日, 北向资金增持君实生物-U22.01万股，连续3日增持。截止当日收盘，沪股通共持有君实生物-U1707.89万股，占流通股2.23%。沪股通增持金额前五个股分别为工业富联、药明康德、巨化股份、传音控股、海光信息。君实生物-U近5个交易日上涨0.68%，沪股通累计增持18.09万股；近20个交易日下跌13.27%，沪股通累计增持243.56万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040809361787522cc7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040809361787522cc7&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425606664","title":"君实生物肾癌免疫疗法获批上市 标志着国内创新药物新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2425606664","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2425606664?lang=zh_cn&edition=full","pubTime":"2024-04-08 08:28","pubTimestamp":1712536110,"startTime":"0","endTime":"0","summary":"快讯正文君实生物肾细胞癌免疫疗法获批上市投资者关注的热点栏目显示，君实生物近日发布公告。公司已收到国家药品监督管理局颁发的《药品注册证书》。该证书标志着特瑞普利单抗与阿昔替尼联合疗法，用于治疗中高危不可切除或转移性肾细胞癌患者。这成为国内首个获得批准的肾癌免疫疗法。此次获批的疗法，将为肾细胞癌患者提供新的治疗选择。和讯竭力但不能证实上述内容的真实性、准确性和原创性，对此和讯不做任何保证和承诺。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404080914548afc757c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404080914548afc757c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425571671","title":"智通港股早知道 | 北京广州等地出台支持医药创新政策 黄金现货价格突破2300美元/盎司","url":"https://stock-news.laohu8.com/highlight/detail?id=2425571671","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2425571671?lang=zh_cn&edition=full","pubTime":"2024-04-08 06:55","pubTimestamp":1712530530,"startTime":"0","endTime":"0","summary":"最高支持50亿元 北京、广州、珠海等地出台支持医药创新政策北京、广州、珠海等多地政府同时出台支持创新医药高质量发展的政策。黄金现货价格突破2300美元/盎司 机构连改三次展望仍赶不上金价上涨高盛今年曾三次修改黄金展望，但仍然没有赶上黄金的涨势。高盛认为年底前，金价将上看2300美元/盎司。报道称，这种方式允许来自中国的廉价服装免关税、几乎不经审查地流入美国。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1099080.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2425645661","title":"AI财经速递｜君实生物获批我国首个肾癌免疫疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2425645661","media":"读创","top":-1,"share":"https://www.laohu8.com/m/news/2425645661?lang=zh_cn&edition=full","pubTime":"2024-04-07 22:14","pubTimestamp":1712499240,"startTime":"0","endTime":"0","summary":"君实生物4月7日晚间公告，近日，公司收到国家药品监督管理局核准签发的《药品注册证书》，特瑞普利单抗联合阿昔替尼用于中高危的不可切除或转移性肾细胞癌患者的一线治疗的新适应症上市申请获得批准，是我国首个获批的肾癌免疫疗法。此次特瑞普利单抗新适应症的获批，基于RENOTORCH研究的数据结果，该研究为我国首个晚期肾癌免疫治疗的关键III期临床研究。截至目前，特瑞普利单抗的8项适应症已于中国获批。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404072219358afad524&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404072219358afad524&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425612145","title":"君实生物(01877.HK)特瑞普利单抗新适应症上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2425612145","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2425612145?lang=zh_cn&edition=full","pubTime":"2024-04-07 20:38","pubTimestamp":1712493480,"startTime":"0","endTime":"0","summary":"君实生物(01877.HK) 公布，收到国家药品监督管理局核准签发《药品注册证书》，特瑞普利单抗(商品名：拓益，产品代号：JS001)联合阿昔替尼用于中高危的不可切除或转移性肾细胞癌患者的一线治疗的新适应症上市申请获得批准，是首内地个获批的肾癌免疫疗法。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-05 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1340455/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2425005610","title":"君实生物特瑞普利单抗获批治疗中高危肾细胞癌，拓益成国内首个获批肾癌免疫疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2425005610","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2425005610?lang=zh_cn&edition=full","pubTime":"2024-04-07 19:35","pubTimestamp":1712489730,"startTime":"0","endTime":"0","summary":"君实生物自主研发的特瑞普利单抗，成为首个获批上市的国产抗PD-1单抗药物。中、高危晚期肾细胞癌患者对新型治疗方案的需求迫切。仁济医院黄翼然教授表示，特瑞普利单抗联合阿昔替尼疗法获批，将为我国晚期肾癌患者带来福音。在国际化布局方面，特瑞普利单抗已在美国获批上市，并获得多项FDA认定，有望进一步拓展海外市场。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404072128418afab7b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404072128418afab7b0&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0827},{"period":"1month","weight":-0.0879},{"period":"3month","weight":-0.3532},{"period":"6month","weight":-0.4621},{"period":"1year","weight":-0.6912},{"period":"ytd","weight":-0.5036}],"compareEarnings":[{"period":"1week","weight":-0.0415},{"period":"1month","weight":-0.0087},{"period":"3month","weight":0.0704},{"period":"6month","weight":-0.0458},{"period":"1year","weight":-0.1955},{"period":"ytd","weight":-0.0388}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海君实生物医药科技股份有限公司是一家主要从事创新驱动型生物制药业务的中国公司。该公司主要开发创新药物，并全球范围内提供临床研究商业化服务。该公司产品覆盖肿瘤免疫治疗、代谢类疾病、炎症或自身免疫性疾病及神经系统疾病等多个治疗领域。该公司的药品主要用于治疗黑色素瘤、鼻咽癌、食管癌、尿路上皮癌、恶性淋巴瘤等。该公司主要于国内及海外市场提供产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.122873},{"month":2,"riseRate":0.833333,"avgChangeRate":0.02917},{"month":3,"riseRate":0.666667,"avgChangeRate":0.049114},{"month":4,"riseRate":0.666667,"avgChangeRate":0.076967},{"month":5,"riseRate":0.2,"avgChangeRate":-0.050803},{"month":6,"riseRate":0.4,"avgChangeRate":-0.020648},{"month":7,"riseRate":0.4,"avgChangeRate":-0.076121},{"month":8,"riseRate":0,"avgChangeRate":-0.093613},{"month":9,"riseRate":0,"avgChangeRate":-0.097134},{"month":10,"riseRate":0.4,"avgChangeRate":0.053036},{"month":11,"riseRate":0.6,"avgChangeRate":0.067975},{"month":12,"riseRate":0.8,"avgChangeRate":0.175695}],"exchange":"SEHK","name":"君实生物","nameEN":"JUNSHI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"君实生物,01877,君实生物股票,君实生物股票老虎,君实生物股票老虎国际,君实生物行情,君实生物股票行情,君实生物股价,君实生物股市,君实生物股票价格,君实生物股票交易,君实生物股票购买,君实生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"君实生物(01877)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供君实生物(01877)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}